Summary & Overview
HCPCS P9073: Platelets, Pheresis, Pathogen-Reduced, Each Unit
HCPCS Level II code P9073 represents a single unit of platelets collected by pheresis that have been processed with pathogen-reduction technology. This code identifies a specific blood product with enhanced infectious risk mitigation, relevant to hospital transfusion services and blood banks. Nationally, pathogen-reduced platelet products are important for improving transfusion safety, managing supply and inventory of specialized components, and aligning clinical practice with institutional transfusion protocols.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical role of pathogen-reduced pheresis platelets, typical sites of service, and payer coverage context. The publication presents benchmarks where available, summarizes relevant policy considerations affecting payment and coding of specialized blood products, and outlines operational implications for supply management and billing workflows.
The content is intended for hospital administrators, transfusion service leaders, clinical billing staff, and policy analysts seeking a national perspective on coding and coverage for pathogen-reduced platelet units. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code P9073 describes platelets collected by pheresis that have undergone pathogen reduction, billed per each unit. The service involves processing donor platelet units using a pathogen-reduction technology intended to reduce infectious risk in transfusable platelet components.
Service type: Blood product — platelet pheresis, pathogen-reduced
Typical site of service: Hospital blood bank, transfusion service, or specialized transfusion center
Clinical & Coding Specifications
Clinical Context
A typical patient receiving P9073 is an adult or pediatric inpatient or outpatient with thrombocytopenia or platelet dysfunction requiring transfusion support, such as a patient undergoing chemotherapy for hematologic malignancy, a patient with aplastic anemia, or a surgical patient with active bleeding and low platelet count. The blood bank supplies apheresis-derived, pathogen‑reduced platelet unit(s) to reduce infectious risk. Clinical workflow: the treating physician documents indication and obtains informed consent; laboratory verifies platelet count and orders transfusion; the transfusion service requests P9073 from blood bank inventory or external supplier; pre‑transfusion testing (type and screen, crossmatch if indicated) and patient identification checks are completed; the platelet unit is issued, transported under controlled conditions to the point of care; nursing administers transfusion while monitoring for reactions; post‑transfusion platelet count and clinical response are documented.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard billing when no additional modifier applies |